Clinical Trials Browser

Active not recruiting × Interventional × Gefitinib × Clear all

Carcinoma, Non-Small-Cell Lung

NCT03040973 2026-04-02

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Phase 2 Active not recruiting

29 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02411448 2026-01-16

RELAY

Phase 3 Active not recruiting

545 enrolled 24 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Phase 1 Active not recruiting

105 enrolled

Thoracic

EGFR-mutant Non-small Cell Lung Cancer

NCT03787992 2025-04-11

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Phase 3 Active not recruiting

358 enrolled

Thoracic

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer

NCT03944772 2025-01-30

ORCHARD

Phase 2 Active not recruiting

247 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04248829 2024-12-03

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Phase 3 Active not recruiting

393 enrolled 13 charts

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT03866499 2024-08-07

A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients

Phase 3 Active not recruiting

369 enrolled

Thoracic

NSCLC

NCT04143607 2024-06-14

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Phase 3 Active not recruiting

337 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

RELAY

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

ORCHARD

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC